QL1706

DB17562InvestigationalProtein Based Therapies

QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4 and Programmed cell death protein 1
Curator reviewed
Code names: PSB205 · QL1706

Resolves to

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with QL1706, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.